OPKO Health, Inc. (OPK)

NASDAQ: OPK · IEX Real-Time Price · USD
1.60
+0.10 (6.67%)
At close: Sep 29, 2023, 4:00 PM
1.62
+0.02 (1.25%)
After-hours: Sep 29, 2023, 7:58 PM EDT
6.67%
Market Cap 1.24B
Revenue (ttm) 868.08M
Net Income (ttm) -209.23M
Shares Out 773.06M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE 64.52
Dividend n/a
Ex-Dividend Date n/a
Volume 3,186,595
Open 1.57
Previous Close 1.50
Day's Range 1.52 - 1.60
52-Week Range 1.00 - 2.24
Beta 1.76
Analysts Strong Buy
Price Target 2.50 (+56.25%)
Earnings Date Nov 7, 2023

About OPK

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers,... [Read more]

Sector Healthcare
IPO Date Nov 2, 1995
Employees 4,196
Stock Exchange NASDAQ
Ticker Symbol OPK
Full Company Profile

Financial Performance

In 2022, OPKO Health's revenue was $1.00 billion, a decrease of -43.42% compared to the previous year's $1.77 billion. Losses were -$328.41 million, 989.5% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for OPK stock is "Strong Buy." The 12-month stock price forecast is $2.5, which is an increase of 56.25% from the latest price.

Price Target
$2.5
(56.25% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Provides Initial $59 Million and up to $168 Million Contingent on Milestones Provides Initial $59 Million and up to $168 Million Contingent on Milestones

2 days ago - GlobeNewsWire

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. fi...

2 months ago - GlobeNewsWire

OPKO Health is the Little Giant of Diversified Healthcare

Diversified healthcare company OPKO Health Inc. NASDAQ: OPK shares may be low priced, but its businesses pipeline of treatments and upside potential may deserve a higher valuation. Shares trade at 1.6...

2 months ago - MarketBeat

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a ...

Other symbols: PFE
3 months ago - Business Wire

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights i...

5 months ago - GlobeNewsWire

OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023

MIAMI, April 25, 2023 (GLOBE NEWSWIRE) --  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financi...

5 months ago - GlobeNewsWire

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

7 months ago - GlobeNewsWire

OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023

MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financ...

8 months ago - GlobeNewsWire

BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings

CINtec ®  PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive ELMWOOD PARK, N.J. , Feb. 9, 2023 /PRNewswire/ -- BioReference® Health LLC, one of the largest full-service spec...

8 months ago - PRNewsWire

OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

MIAMI, Jan. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 41st Annual J.P. Morgan Healthcare Conference being held January 9...

9 months ago - GlobeNewsWire

OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

11 months ago - GlobeNewsWire

OPKO Health And 2 Other Penny Stocks Are Aggressively Buying - Medalist Diversified REIT (NASDAQ:MDRR), Great Elm Group (NASDAQ:GEG)

US crude oil futures traded higher on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: MDRRGEG
1 year ago - Benzinga

OPKO Health Announces Leadership Changes for BioReference Laboratories

MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role ...

1 year ago - GlobeNewsWire

OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022

MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. fi...

1 year ago - GlobeNewsWire

OPKO Health And 2 More Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones surged by more than 800 points on Friday. Investors, meanwhile, focused on some notable insider trades.

1 year ago - Benzinga

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

Transaction to be discussed during OPKO's first quarter 2022 conference call today at 4:30 p.m. ET

1 year ago - GlobeNewsWire

11 Stocks Moving Towards A VWAP Breakout: Tellurian, SM Energy, Freshworks And More

Volume-weighted average price or VWAP is the ratio of total volume traded divided by the total volume traded for a chosen time frame. VWAP is an important indicator for intraday trading as it graphica...

1 year ago - Benzinga

GeneDx Announces Discovery of 200 New and Expanded Genetic Conditions

New research underscores the value of sharing genomic information to advance gene matching for diagnosis and discovery GAITHERSBURG, Md., March 16, 2022 /PRNewswire/ -- GeneDx, Inc., a leader in genom...

1 year ago - PRNewsWire

Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease

ROSWELL, Ga., March 1, 2022 /PRNewswire/ -- Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic anal...

1 year ago - PRNewsWire

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

1 year ago - GlobeNewsWire

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financ...

1 year ago - GlobeNewsWire

Pfizer and OPKO's Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation ...

Other symbols: PFE
1 year ago - Business Wire

RAYALDEE® Launched in Germany by OPKO Health's Licensee, VFMCRP

MIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE® (extended re...

1 year ago - GlobeNewsWire

Pfizer, Opko Shares Fall After FDA Declines to Approve Somatrogon

Pfizer said it is evaluating the FDA's comments and will work with the agency "to determine an appropriate path forward."

Other symbols: PFE
1 year ago - Barrons

Pfizer - OPKO Health's Growth Hormone Deficiency Candidate Receives FDA Response Letter

The FDA has issued a Complete Response Letter (CRL) to Pfizer Inc (NYSE: PFE) and OPKO Health Inc's (NASDAQ: OPK) somatrogon.  Somatrogon is an investigational once-weekly long-acting recombinant huma...

Other symbols: PFE
1 year ago - Benzinga